Archive for the 'Drug resistance' Category
Monitoring antimalarial drug resistance with molecular tools
0 Comments Published October 27th, 2008 in Surveillance, Drug resistanceMillions of people get treated for malaria every year so its important to use an antimalarial which works. Treatment failures result in a prolonged illness for the patient with an increased risk of severe malaria and death. In addition, they contribute to increased malaria transmission. Makes sense right? However, the parasite has an amazing ability […]
Poor quality of private sector antimalarials
0 Comments Published May 30th, 2008 in Treatment, Drug resistanceBate et al. tested antimalarial quality for several drugs in 6 countries across sub-Saharan Africa and found an alarming 35% were substandard as gauged by thin layer chromatography or dissolution tests. The authors did not attempt to assess whether counterfeit or not as the outcome would remain the same - i.e. the drugs are substandard […]
In early April of this year a Vietnamese news source carried an article about the challenges of malaria control and the possibility of future malaria epidemics. A substantial portion of the piece focused on antimalarial resistance, including high failure rates of chloroquine and sulphadoxine-pyrimethamine. What was surprising was a passing mention of artesunate failures:
… while […]
Protecting artemisinin combination therapies - treatment failures in Southeast Asia
1 Comment Published May 16th, 2008 in Drug resistanceArtemisinin combination therapies (ACTs) have become the global standard for the treatment of Plasmodium falciparum malaria in areas with existing or emerging drug resistance. ACTs have several advantages: combination therapy diminishes the probability of de novo mutation, artemisinin is the most schizonticidal drug and reduces parasite biomass very rapidly resulting in faster clearance rates, and […]
GSK ends its antifolate drugs Lapdap and Dacart
0 Comments Published March 5th, 2008 in Treatment, Drug resistanceGlaxoSmithKline pulled Lapdap (chloroproguanil-dapsone) from the market and ended the development of Dacart (Lapdap+artesunate) after phase III trials of the drugs showed significant hemoglobin reductions in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Patient’s with G6PD deficiency have weaker red blood cell membranes which can rupture when exposed to oxidative stress caused by certain drugs […]
Overdiagnosis of malaria hurts the patient (and you and me)
0 Comments Published February 21st, 2008 in Drug resistance, DiagnosisMuch of the world still diagnoses malaria clinically (based on symptoms alone without testing for the presence of the parasite). Recently, a Liverpool team working in Mozambique examined the cost to individual patients resulting from the clinical diagnosis of malaria (Malaria Journal - open access). The findings were striking but certainly not surprising. 23 percent […]
Search
About
You are currently browsing the topnaman | Malaria blog weblog archives for the 'Drug resistance' category.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.Latest
- Fighting malaria since the Skeeter beaters
- Mosquito syringes and more funded by the Gates foundations grand challenges
- Monitoring antimalarial drug resistance with molecular tools
- Survival - a new BBC global health series showcases malaria
- Launch of the Global Malaria Action Plan
- 2008 World malaria report released
- Resurrecting the past to create a new malaria vaccine
- Malaria elimination or eradication vs control - what is the big deal?
- The grand challenge of eradication - Gates Foundation is looking for new tools
- Malaria (and other communicable diseases) in Southeast Asia
Archives
Categories
- Advocacy (4)
- Climate (2)
- Communication (2)
- Delivery (2)
- Diagnosis (2)
- Drug resistance (6)
- Policy (9)
- Random (2)
- Research (3)
- Surveillance (5)
- Treatment (3)
- Vector control (2)
Categories
- Advocacy (4)
- Climate (2)
- Communication (2)
- Delivery (2)
- Diagnosis (2)
- Drug resistance (6)
- Policy (9)
- Random (2)
- Research (3)
- Surveillance (5)
- Treatment (3)
- Vector control (2)
